Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study

Status Completed

Clinical Trial Summary

Osteogenesis imperfecta (OI) is a genetic disease for which there is currently no known cure. OI causes the osteoblasts (bone-forming cells in the body) to grow poorly, which slows the growth of children with the disease and causes their bones to bend and break easily. Some forms of osteogenesis imperfecta may cause severe disability and even death. In previous research studies performed at St. Jude, it was found that children treated with bone marrow transplant (infusion of healthy immature blood-forming cells) began to grow faster, had more minerals (material that helps make the bones strong) in their bones, and broke their bones less often than before the bone marrow transplant. Several months after the bone marrow transplant however, body growth once again began to slow down. In this research study, children with osteogenesis imperfecta will receive another infusion of bone marrow cells but without any chemotherapy. The marrow cells will come from the same bone marrow donor as their previous bone marrow transplant. It is hoped that by removing the CD3+ cells (a type of white blood cells that attack other cells that are not like themselves) from the donated bone marrow, the subject's body will be infused quite safely and that body growth and bone strength will increase. The CD3+ cells will be removed from the donor bone marrow by use of a machine called the CliniMACS System. This machine has not been approved for use in the United States by the Food and Drug Administration (FDA). The use of this device is considered experimental.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Osteogenesis Imperfecta

Clinical Trial Details

NCT number	NCT00187018
Study type	Interventional
Source	St. Jude Children's Research Hospital
Contact
Status	Completed
Phase	N/A
Start date	March 2004
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03557567` - NGS Strategy Effectiveness in Molecular Diagnosis
Not yet recruiting	`NCT05559801` - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)	Phase 1/Phase 2
Active, not recruiting	`NCT02531087` - Urinary Biomarkers of OI Pathobiology
Completed	`NCT01713231` - Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta	Phase 4
Completed	`NCT00655681` - Prevention of Post Operative Bone Loss in Children	N/A
Recruiting	`NCT06065111` - Study of Osteogenesis Imperfecta Tendon
Withdrawn	`NCT03216486` - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta	Phase 2
Recruiting	`NCT06086613` - A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers	Phase 1
Completed	`NCT04009733` - Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study	N/A
Completed	`NCT04231916` - High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta	N/A
Active, not recruiting	`NCT02814591` - Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
Completed	`NCT00982124` - An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta	Phase 3
Completed	`NCT00001305` - Growth Hormone Therapy in Osteogenesis Imperfecta	Phase 3
Completed	`NCT04119388` - Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta	N/A
Terminated	`NCT01679080` - The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta	Phase 2
Completed	`NCT00106028` - Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children	Phase 3
Recruiting	`NCT04152551` - Effects of Bisphosphonates on OI-Related Hearing Loss	Phase 4
Completed	`NCT00705120` - Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation	Phase 1
Recruiting	`NCT04169568` - Osteogenesis Imperfecta Blood Pressure Study
Completed	`NCT03064074` - Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta	Phase 1